Track And Trace Deadline Could Slip Again After Worries Over Inferencing
Executive Summary
Generic representative raises concerns about errors from bulk scanning, while distributors and pharmacies feel failure to include inferencing will hinder patient access to drugs.
You may also be interested in...
Next User Fee Cycle Should Focus On Policy Improvements, Gottlieb Says
US FDA commissioner wants to focus on new policies that will improve innovation and move beyond incremental process improvements.
FDA’s Delay Issuing DSCSA Grandfathering Guidance Creating Problems For Manufacturers
US agency's delay in issuing guidance for how it intends to handle un-serialized 'grandfathered' drug products is creating headaches for manufacturers and other parties in the pharmaceutical distribution chain.
FDA Drafts Guidance To Dispel Confusion About DSCSA Trading Partners
FDA draft guidance clarifies the roles of the different supply chain partners under the Drug Supply Chain Security Act. While much attention has focused on the serialization challenges in implementing DSCSA, less attention has been paid to which trading partners are authorized to transfer products.